GPP
SYRE icon

Great Point Partners’s Spyre Therapeutics SYRE Stock Holding History

Great Point Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-134,612
Closed -$3.16M – 37
2024
Q2 		$3.16M Buy
134,612
+9,612
+8% +$324K 0.61% 31
2024
Q1 		$4.74M Hold
125,000
– – 0.74% 33
2023
Q4 		$2.69M Buy
+125,000
New +$1.72M 0.46% 30
2022
Q4 		– Sell
-100,000
Closed -$1.31M – 54
2022
Q3 		$1.31M Hold
100,000
– – 0.32% 39
2022
Q2 		$1.26M Buy
+100,000
New +$3.5M 0.3% 35
2022
Q1 		– Sell
-36,410
Closed -$4.32M – 40
2021
Q4 		$4.32M Buy
36,410
+410
+1% +$64.7K 0.96% 31
2021
Q3 		$7.16M Hold
36,000
– – 1.67% 27
2021
Q2 		$6.26M Buy
36,000
+15,884
+79% +$2.89M 1.31% 29
2021
Q1 		$3.98M Buy
+20,116
New +$3.86M 0.82% 27

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's SYRE Position: Q3 2024 in Review

Great Point Partners sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 134,612 shares — an estimated $3.16M sold.

Great Point Partners first reported a position in SYRE in Q1 2021 and held it in 9 quarters. The position peaked at $7.16M in Q3 2021. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

  • Great Point Partners reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Great Point Partners sold 134,612 Spyre Therapeutics shares in Q3 2024, an estimated $3.16M.
  • Great Point Partners first reported a position in Spyre Therapeutics in Q1 2021 and held it in 9 quarters.
  • Great Point Partners's Spyre Therapeutics position peaked at $7.16M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.